Antibody-dependent cellular cytotoxicity (ADCC) plays an important role in anti-tumor activity of therapeutic monoclonal antibodies (mAbs) targeting tumor cells.[1]–[3] To date, many mAbs exhibiting ADCC activity have been approved and have contributed to anticancer therapy (e.g., the anti-EGFR (epidermal growth factor receptor) mAb cetuximab for colorectal cancers, the anti-CD20 mAb rituximab for B-cell lymphomas, and the anti-HER2 mAb trastuzumab for metastatic breast cancers). This evidence concerns the gene EGFR and B-cell non-Hodgkin lymphoma.